Den europeiske union - norsk - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - granisetron - vomiting; cancer - antiemetika og antinauseants, , serotonin (5ht3) antagonister - forebygging av kvalme og oppkast hos pasienter som får moderat eller svært emetogen kjemoterapi, med eller uten cisplatin, i opptil fem sammenhengende dager. sancuso kan brukes av pasienter som får sin første kjemoterapi diett eller hos pasienter som tidligere har fått kjemoterapi.

Den europeiske union - norsk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter for dermatitt, unntatt kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Norge - norsk - Statens legemiddelverk

aristo pharma gmbh - paroksetinhydrokloridhemihydrat - tablett, filmdrasjert - 20 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - venlafaksinhydroklorid - depottablett - 150 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - venlafaksinhydroklorid - depottablett - 75 mg

Norge - norsk - Statens legemiddelverk

medical valley invest ab - venlafaksinhydroklorid - depottablett - 225 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - venlafaksinhydroklorid - depotkapsel, hard - 75 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - venlafaksinhydroklorid - depotkapsel, hard - 150 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - venlafaksinhydroklorid - depotkapsel, hard - 75 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - venlafaksinhydroklorid - depotkapsel, hard - 37.5 mg